KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) EBIT Margin: 2014-2025

Historic EBIT Margin for Aurinia Pharmaceuticals (AUPH) over the last 5 years, with Sep 2025 value amounting to 40.49%.

  • Aurinia Pharmaceuticals' EBIT Margin rose 2315.00% to 40.49% in Q3 2025 from the same period last year, while for Sep 2025 it was 26.34%, marking a year-over-year increase of 4117.00%. This contributed to the annual value of -1.99% for FY2024, which is 5025.00% up from last year.
  • As of Q3 2025, Aurinia Pharmaceuticals' EBIT Margin stood at 40.49%, which was up 41.14% from 28.69% recorded in Q2 2025.
  • Aurinia Pharmaceuticals' EBIT Margin's 5-year high stood at 40.49% during Q3 2025, with a 5-year trough of -5,529.87% in Q1 2021.
  • Over the past 3 years, Aurinia Pharmaceuticals' median EBIT Margin value was -2.79% (recorded in 2024), while the average stood at -11.90%.
  • The largest annual percentage gain for Aurinia Pharmaceuticals' EBIT Margin in the last 5 years was 14,557,048bps (2021), contrasted with its biggest fall of 12,364bps (2021).
  • Aurinia Pharmaceuticals' EBIT Margin (Quarterly) stood at -139.74% in 2021, then spiked by 4,092bps to -98.82% in 2022, then soared by 3,302bps to -65.80% in 2023, then surged by 6,302bps to -2.79% in 2024, then spiked by 2,315bps to 40.49% in 2025.
  • Its EBIT Margin was 40.49% in Q3 2025, compared to 28.69% in Q2 2025 and 34.97% in Q1 2025.